Manufacturer Supply Linagliptin and Related Intermediates:
Linagliptin CAS 668270-12-0
Linagliptin Parent Nucleus Intermediate CAS 853029-57-9
8-Bromo-3-Methylxanthine CAS 93703-24-3
8-Bromo-7-(2-butyn-1-yl)-3-methylxanthine CAS 666816-98-4
2-(Chloromethyl)-4-Methylquinazoline CAS 109113-72-6
(R)-3-(Boc-Amino)piperidine CAS 309956-78-3
(R)-(-)-3-Aminopiperidine Dihydrochloride CAS 334618-23-4
1-Bromo-2-Butyne CAS 3355-28-0
| Chemical Name | 8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione |
| Synonyms | Linagliptin Parent Nucleus; Linagliptin Intermediate F |
| CAS Number | 853029-57-9 |
| CAT Number | RF-PI502 |
| Stock Status | In Stock, Production Scale Up to Tons |
| Molecular Formula | C20H17BrN6O2 |
| Molecular Weight | 453.29 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Light Yellow Powder |
| Identification | IR/HPLC |
| Purity | ≥99.0% |
| Water (K.F) | ≤1.0% |
| Residue on Ignition | ≤0.50% |
| Total Impurities | ≤1.0% |
| Test Standard | Enterprise Standard |
| Usage | Intermediate for Linagliptin (CAS: 668270-12-0) |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.
8-Bromo-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (CAS: 853029-57-9) is the parent nucleus of Linagliptin (CAS: 668270-12-0). Linagliptin (trade names Tradjenta and Trajetna) is an inhibitor of dipeptidyl peptidase-4 (DPP-4) that was approved by the U.S. FDA in May 2011 for the treatment of Type 2 diabetes along with diet and exercise. Linagliptin (BI-1356) has been described as a potent highly selective, slow-off rate and long acting inhibitor of DPP-4. Linagliptin arose from optimization efforts of xanthine-based DPP-4 inhibitors with the initial lead identified from an HTS campaign.